Oral Semaglutide 50 mg Taken Once per Day in Adults with Overweight or Obesity (OASIS 1): a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial
Lancet. 2023. DOI: 10.1016/S0140-6736(23)01185-6
Oral semaglutide 7 mg and 14 mg once-daily are approved for the treatment of T2D and improve glycaemic control with accompanying body weight reductions. A higher dose of once-daily oral semaglutide 50 mg is currently being investigated for the treatment of obesity in people with overweight or obesity, and for glycaemic control in people with T2D. The OASIS 1 trial assessed once-daily oral semaglutide 50 mg in adults with overweight or obesity, without T2D.
Oral semaglutide 50 mg led to a superior and clinically meaningful decrease in body weight compared with placebo at week 68, as measured by change from baseline and the proportion of participants achieving ≥5% body weight reduction. These findings were accompanied by improvements in cardiometabolic risk factors. AEs were more frequent with oral semaglutide 50 mg than placebo, particularly GI AEs.
Keywords:
